Eupraxia Pharmaceuticals (TSX:EPRX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.25) by 8 percent. This is a 11.54 percent increase over losses of $(0.26) per share from the same period last year.